DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

British Journal of Clinical Pharmacology
Felicia Stefania FalvellaFilippo Pietrantonio

Abstract

Triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan is a standard therapy for metastatic colorectal cancer (CRC). Single nucleotide polymorphisms (SNPs) in DPYD and UGT1A1 influence fluoropyrimdines and irinotecan adverse events (AEs). Low frequency DPYD variants (c.1905 + 1G > A, c.1679 T > G, c.2846A > T) are validated but more frequent ones (c.496A > G, c.1129-5923C > G and c.1896 T > C) are not. rs895819 T > C polymorphism in hsa-mir-27a is associated with reduced DPD activity. In this study, we evaluated the clinical usefulness of a pharmacogenetic panel for patients receiving triplet combinations. Germline DNA was available from 64 CRC patients enrolled between 2008 and 2013 in two phase II trials of capecitabine, oxaliplatin and irinotecan plus bevacizumab or cetuximab. SNPs were determined by Real-Time PCR. We evaluated the functional variants in DPYD (rare: c.1905 + 1G > A, c.1679 T > G, c.2846A > T; most common: c.496A > G, c.1129-5923C > G, c.1896 T > C), hsa-mir-27a (rs895819) and UGT1A1 (*28) genes to assess their association with grade 3-4 AEs. None of the patients carried rare DPYD variants. We found DPYD c.496A > G, c.1129-5923C > G, c.1896 T > C in heterozygosity in 19%, 5% and 8%, respectiv...Continue Reading

References

Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyHans-Joachim Schmoll
Sep 8, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BajettaS Pusceddu
Oct 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles S FuchsJosé Barrueco
Jan 8, 2009·American Journal of Epidemiology·Santiago RodriguezIan N M Day
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Jul 10, 2010·Anti-cancer Drugs·Linda J M OostendorpPetronella B Ottevanger
Jul 7, 2011·Chest·David L Streiner, Geoffrey R Norman
Feb 7, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi HirotaIchiro Ieiri
Oct 22, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F LoupakisA Falcone
Feb 5, 2014·Pharmacogenetics and Genomics·Julia M BarbarinoRuss B Altman
Jun 25, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Oct 23, 2014·The New England Journal of Medicine·Fotios LoupakisAlfredo Falcone
Dec 30, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T GruenbergerR Adam
Feb 1, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Maria Di BartolomeoEmilio Bajetta
May 1, 2014·Personalized Medicine·Felicia Stefania FalvellaFilippo Pietrantonio

❮ Previous
Next ❯

Citations

Apr 24, 2015·International Journal of Molecular Sciences·Felicia Stefania FalvellaFilippo Pietrantonio
Dec 31, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Carin A T C LunenburgHans Gelderblom
Aug 5, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Paolo PellegrinoSonia Radice
Jun 18, 2015·Frontiers in Pharmacology·Stefania CheliFelicia S Falvella
Sep 13, 2016·International Journal of Molecular Sciences·Vid MlakarMarc Ansari
Oct 4, 2016·Drug Discovery Today·Harshali PatilRupinder K Kanwar
Jan 12, 2017·Clinical Pharmacology and Therapeutics·R RoncatoG Toffoli
Sep 13, 2019·Expert Opinion on Drug Metabolism & Toxicology·Giuseppe MiscioDavide Seripa
Feb 21, 2019·The New England Journal of Medicine·Aditya BardiaKevin Kalinsky
Oct 28, 2017·Frontiers in Pharmacology·Nurul-Syakima Ab MutalibRahman Jamal
Jul 1, 2020·Expert Opinion on Drug Metabolism & Toxicology·Gloria RavegniniSabrina Angelini
Nov 25, 2020·Journal of Personalized Medicine·Ana Rita SimõesÁngel Carracedo
Nov 26, 2020·Pharmacogenomics and Personalized Medicine·Gemma BrueraUNKNOWN Oncology Network ASL1 Abruzzo
Mar 19, 2021·Pharmacogenomics·Amirsaeed Sabeti AghabozorgiMohammad Reza Abbaszadegan
Mar 27, 2021·Frontiers in Genetics·Jorge E B da RochaMichèle Ramsay
Aug 28, 2021·Journal of Personalized Medicine·Priscila VillalvazoLuis Andrés López-Fernández

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jim Cassidy
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Société Canadienne Des Sciences Pharmaceutiques
Solen PichereauHélène Bourgoin
© 2021 Meta ULC. All rights reserved